Characteristics and Dysbiosis of the Gut Microbiome in Renal Transplant RecipientsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated the composition of the gut microbiome in renal transplant recipients (RTRs) and compared it with that of healthy controls. The researchers used 16S rRNA sequencing of fecal samples to characterize microbiome composition and diversity. They then applied multivariate association with linear models (MaAsLin) to identify clinical and pharmacological determinants of the gut microbiome in RTRs, including immunosuppressive drugs and antibiotic exposure.
Who was studied?
The study included 139 renal transplant recipients (50% male, mean age 58.3 plus or minus 12.8 years) and 105 healthy controls (57% male, mean age 59.2 plus or minus 10.6 years), all participants in the TransplantLines Biobank and Cohort Study (NCT03272841). The median time since transplantation among RTRs was 6.0 years, with a range of 1.5 to 12.5 years. Fecal samples were collected from both groups for microbiome analysis.
What were the most important findings?
The gut microbiome composition of RTRs was significantly different from that of healthy controls, and RTRs had significantly lower gut microbiome diversity (p less than 0.01). Proton-pump inhibitors, mycophenolate mofetil, and estimated glomerular filtration rate (eGFR) were identified as significant determinants of the gut microbiome in RTRs (p less than 0.05). These findings point to specific medications and kidney function as key factors shaping post-transplant dysbiosis, rather than transplantation alone.
What are the greatest implications of this study?
The findings indicate that renal transplant recipients experience measurable intestinal dysbiosis linked to specific modifiable factors, particularly proton-pump inhibitor use and mycophenolate mofetil therapy. This suggests that clinicians managing RTRs might consider the gut microbiome impact of routine medication choices as part of post-transplant care. Further research could explore whether adjusting these determinants influences microbiome recovery or long-term transplant outcomes.